AR098880A2 - Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión - Google Patents

Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión

Info

Publication number
AR098880A2
AR098880A2 ARP140104816A ARP140104816A AR098880A2 AR 098880 A2 AR098880 A2 AR 098880A2 AR P140104816 A ARP140104816 A AR P140104816A AR P140104816 A ARP140104816 A AR P140104816A AR 098880 A2 AR098880 A2 AR 098880A2
Authority
AR
Argentina
Prior art keywords
mmol
concentration
electrolyte
protective solution
contained
Prior art date
Application number
ARP140104816A
Other languages
English (en)
Original Assignee
Dr Franz Köhler Chemie Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Franz Köhler Chemie Gmbh filed Critical Dr Franz Köhler Chemie Gmbh
Publication of AR098880A2 publication Critical patent/AR098880A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02Preservation of living parts
    • A01N1/0205Chemical aspects
    • A01N1/021Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0226Physiologically active agents, i.e. substances affecting physiological processes of cells and tissue to be preserved, e.g. anti-oxidants or nutrients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physiology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Una solución protectora para prevenir daños isquémicos en los órganos, o en sistemas celulares aislados, o en componentes de tejido después de la perfusión, operación, trasplante, o crio-conservación y subsiguiente reperfusión, que comprende un electrolito seleccionado del grupo que consiste en iones alcalinos y iones alcalino-térreos, un buffer, un poliol y/o un sacárido, en donde dicha solución tiene una osmolaridad de 290 mosm/L a 350 mosm/L, como también un pH con un valor de 6,8 a 7,4 y comprende ácido 3,4 dimetoxi-N-metiIbenzohidroxámico y/o una sal del mismo, dicha composición además comprende N-acetilhistidina como un agente buffer en combinación con arginina, con un contenido aniónico de aspartato, en la cual el ácido 3,4-dimetoxi-N-metilbenzohidroxámico y/o una sal del mismo está comprendido en una cantidad de hasta 10 mmol/L, en la cual la N-acetilhistidina está comprendida en una concentración de 30 mmol/L a 265 mmol/L, en la cual el sodio está contenido deliberadamente como un electrolito a una concentración de 10 mmol/L a 80 mmol/L, en la cual el potasio está contenido deliberadamente como un electrolito a una concentración de 5 mmol/L a 25 mmol/L, en la cual el magnesio está contenido deliberadamente como un electrolito a una concentración de 3,5 mmol/L a 27 mmol/L, en la cual el calcio está contenido deliberadamente como un electrolito a una concentración de 0,005 mmol/L a 0,095 mmol/L, en donde el aspartato está contenido a una concentración de hasta 140 mmol/L, y en donde el a-cetoglutarato está contenido a una concentración de 1 mmol/L a 9 mmol/L. Reivindicación 2: Solución protectora de acuerdo con la reivindicación 1, caracterizada porque comprende una adición de un derivado del ácido 6-hidroxi-2,5,7,8-tetrametilcromán-2-carboxílico, preferentemente del metil éster respectivo. Reivindicación 3: Solución protectora de acuerdo con una cualquiera de las reivindicaciones precedentes, caracterizada porque tiene un contenido de catión de lisina y/o derivado de lisina, preferentemente dipéptidos que contienen lisina. Reivindicación 5: Solución protectora de acuerdo con una cualquiera de las reivindicaciones 2 a 4, caracterizada porque el derivado del ácido 6-hidroxi-2,5,7,8-tetrametiIcromán-2-carboxílico, preferentemente como el derivado de metil éster, está comprendido en una concentración de hasta aproximadamente 10 mmoI/L.
ARP140104816A 2002-05-17 2014-12-19 Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión AR098880A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10222561A DE10222561B4 (de) 2002-05-17 2002-05-17 Protektive Lösung zur Verhinderung von Ischämieschäden

Publications (1)

Publication Number Publication Date
AR098880A2 true AR098880A2 (es) 2016-06-22

Family

ID=29265373

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030101726A AR039819A1 (es) 2002-05-17 2003-05-16 Solucion protectora para evitar danos isquemicos en organos
ARP140104816A AR098880A2 (es) 2002-05-17 2014-12-19 Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030101726A AR039819A1 (es) 2002-05-17 2003-05-16 Solucion protectora para evitar danos isquemicos en organos

Country Status (13)

Country Link
US (2) US7977383B2 (es)
EP (2) EP1362511B1 (es)
JP (1) JP4603246B2 (es)
KR (2) KR101014990B1 (es)
CN (1) CN100448440C (es)
AR (2) AR039819A1 (es)
AT (2) ATE446676T1 (es)
BR (1) BRPI0301159B8 (es)
CA (1) CA2429097C (es)
DE (4) DE10222561B4 (es)
DK (1) DK1859679T3 (es)
ES (2) ES2362867T3 (es)
MX (1) MXPA03004315A (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10222561B4 (de) 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden
CA2564868C (en) 2004-04-28 2013-11-26 Molecules For Health, Inc. Methods for treating or preventing restenosis and other vascular proliferative disorders
WO2005115141A1 (ja) * 2004-05-26 2005-12-08 National University Corporation Kagawa University 希少糖を利用した細胞・組織・臓器保存液及び該液を用いる保存方法
DE102007026392A1 (de) * 2007-06-06 2008-12-11 Bayer Healthcare Ag Lösungen für die Perfusion und Konservierung von Organen und Geweben
EP2030615A3 (en) * 2007-08-13 2009-12-02 ELFORD, Howard L. Ribonucleotide reductase inhibitors for use in the treatment or prevention of neuroinflammatory or autoimmune diseases
US8835104B2 (en) 2007-12-20 2014-09-16 Fenwal, Inc. Medium and methods for the storage of platelets
JP5705324B2 (ja) * 2010-09-01 2015-04-22 パフュージョン・フルイド・テクノロジーズ・インコーポレイテッドPerfusion Fluid Technologies, Inc. 灌流組成物
WO2012139017A1 (en) 2011-04-07 2012-10-11 Fenwal, Inc. Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates
BRPI1101935B1 (pt) * 2011-04-15 2017-12-12 Universidade Federal De Minas Gerais Antioxidant composition for preservation of organs and fabrics
DE102012005177A1 (de) 2012-03-16 2013-09-19 Bitop Ag Organlagerlösung
CN103238586B (zh) * 2013-03-28 2014-03-26 辽宁亿灵科创生物医药科技有限公司 一种心肌脏器保存液制备方法
EP2821081A1 (en) * 2013-07-05 2015-01-07 ResuSciTec GmbH Protective solution for preventing or reducing reperfusion injury of the brain and the whole body
SI3086793T1 (sl) 2013-12-24 2022-10-28 Virginia Commonwealth University Uporaba oksigeniranih holesterol sulfatov (OCS) za zdravljenje ledvične disfunkcije
WO2017192413A1 (en) 2016-05-01 2017-11-09 The Regents Of The University Of California Glutarate compounds for treating ischemia-reperfusion injuries
DE102016125414A1 (de) 2016-12-22 2018-06-28 Bitop Ag Zusammensetzung enthaltend N-Acetyldiaminobuttersäure
CN110536687B (zh) * 2018-03-27 2022-12-16 华东理工大学 N-羟基吡啶酮类化合物及其用途
KR20200069995A (ko) 2018-12-08 2020-06-17 이은지 접이식 빗자루
EP4248959A1 (en) * 2022-03-22 2023-09-27 Dr. Franz Köhler Chemie GmbH Preparation for reduction of pathological iron overload

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH639270A5 (de) 1978-12-14 1983-11-15 Koehler Franz Dr Chemie Kg Protektive loesung fuer herz und niere.
ATE11736T1 (de) * 1980-12-23 1985-02-15 Dr. Franz Koehler Chemie Gmbh Protektive loesung fuer herz und niere und verfahren zu deren herstellung.
US4419365A (en) 1981-12-21 1983-12-06 Ciba-Geigy Corporation Method of treating Alzheimer's disease
US4562006A (en) * 1984-01-11 1985-12-31 Warner-Lambert Company Cycloheptadiene derivatives
US4607053A (en) * 1984-05-17 1986-08-19 E. R. Squibb & Sons, Inc. Arylhydroxamates useful as antiallergy agents
US4604407A (en) * 1985-04-04 1986-08-05 E. R. Squibb & Sons, Inc. Hydroxamates
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
DK36389A (da) 1988-02-05 1989-08-06 Eastman Kodak Co Praeparat og fremgangsmaade til at forebygge vaevskader ved reperfusion
WO1991015215A1 (en) 1990-03-30 1991-10-17 Biomedical Frontiers, Inc. Fluid resuscitation
JPH11514326A (ja) 1990-03-30 1999-12-07 バイオメディカル フロンティアーズ インコーポレイテッド 液体蘇生用医薬物
JP2768799B2 (ja) 1990-04-12 1998-06-25 株式会社大塚製薬工場 心筋保護液
AU8513191A (en) * 1990-09-10 1992-03-30 Austin L. Shug Composition and method for protecting the heart during reperfusion
JP2860301B2 (ja) 1990-09-19 1999-02-24 ヘキスト・マリオン・ルセル株式会社 臓器保存用溶液
GB9024820D0 (en) * 1990-11-15 1991-01-02 Davies Michael J Pharmaceutical compositions
US5498427A (en) * 1990-11-20 1996-03-12 Pasteur Merieux Serums Et Vaccines Solutions for the perfusion, preservation and reperfusion of organs
US5290766A (en) * 1991-02-18 1994-03-01 The National Heart Foundation Of New Zealand Cardioplegic compositions
US5405742A (en) * 1993-07-16 1995-04-11 Cyromedical Sciences, Inc. Solutions for tissue preservation and bloodless surgery and methods using same
EP0713363B1 (en) * 1993-08-12 2002-06-12 The University Of North Carolina At Chapel Hill Rinse solution for organs and tissues
US6321909B1 (en) * 1997-02-13 2001-11-27 Sky High, Llc System for storing polyethylene glycol solutions
EP0938896A1 (en) * 1998-01-15 1999-09-01 Novartis AG Autoclavable pharmaceutical compositions containing a chelating agent
US6365338B1 (en) * 1999-04-27 2002-04-02 David A. Bull Organ preservative solution containing trehalose, anti-oxidant, cations and an energy source
DE10222561B4 (de) 2002-05-17 2009-12-10 Dr. Franz Köhler Chemie GmbH Protektive Lösung zur Verhinderung von Ischämieschäden

Also Published As

Publication number Publication date
KR20100093023A (ko) 2010-08-24
AR039819A1 (es) 2005-03-02
JP2004002418A (ja) 2004-01-08
ATE446676T1 (de) 2009-11-15
DK1859679T3 (da) 2010-03-15
MXPA03004315A (es) 2005-02-14
US20110300237A1 (en) 2011-12-08
CN100448440C (zh) 2009-01-07
DE50313573D1 (de) 2011-05-12
KR20030089495A (ko) 2003-11-21
CA2429097C (en) 2013-06-18
EP1859679B1 (de) 2009-10-28
DE50312079D1 (de) 2009-12-10
ES2362867T3 (es) 2011-07-14
DE10262084B4 (de) 2009-12-24
US7977383B2 (en) 2011-07-12
EP1859679A1 (de) 2007-11-28
EP1362511A1 (de) 2003-11-19
BR0301159A (pt) 2004-08-17
KR101014990B1 (ko) 2011-02-16
ES2335145T3 (es) 2010-03-22
ATE503383T1 (de) 2011-04-15
EP1362511B1 (de) 2011-03-30
CN1480132A (zh) 2004-03-10
DE10222561A1 (de) 2003-12-04
US20030215781A1 (en) 2003-11-20
KR101061293B1 (ko) 2011-08-31
BRPI0301159B1 (pt) 2018-05-15
DE10222561B4 (de) 2009-12-10
JP4603246B2 (ja) 2010-12-22
US9603354B2 (en) 2017-03-28
CA2429097A1 (en) 2003-11-17
BRPI0301159B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
AR098880A2 (es) Solución protectora para prevenir daños isquémicos en los órganos o en sistemas celulares aislados o en componentes de tejido después de la perfusión, operación, transplante o crio-conservación y subsiguiente reperfusión
Aisen et al. Ultramicroscopic and biochemical changes in ram spermatozoa cryopreserved with trehalose-based hypertonic extenders
Malo et al. Anti-oxidant supplementation improves boar sperm characteristics and fertility after cryopreservation: comparison between cysteine and rosemary (Rosmarinus officinalis)
Çoyan et al. Effects of cysteine and ergothioneine on post-thawed Merino ram sperm and biochemical parameters
AR072250A1 (es) COMPOSICIONES DE INSULINA DE ACCION SUPERRAPIDA. BOMBA DE INSULINA, DISPENSADOR. SISTEMA DE LAZO CERRADO. METODO PARA PREPARAR COMPOSICIoN, USO. COMBINACION. KIT.
JP2014516981A5 (es)
Öztürk et al. Cryobiology and cryopreservation of sperm
AR095964A1 (es) Formulaciones para la preservación de órganos y tejidos con mayor estabilidad y vida útil
RU2010151977A (ru) Водный раствор для консервации тканей и органов
EA201691066A1 (ru) Растворы для повышения стабильности и срок годности раствора для консервирования органов и тканей
JP3694730B2 (ja) 組織の冷却保存液
Tomalty et al. Kidney preservation at subzero temperatures using a novel storage solution and insect ice-binding proteins
PE20081321A1 (es) Composicion microbicida acuosa estabilizada contra la degradacion por luz ultravioleta en frutas o vegetales comestibles
JP2007224004A (ja) 超小型豚の人工授精用精液の希釈保存剤。
KR101546487B1 (ko) 저밀도 지질단백질과 항산화제를 포함하는 정자 동결보존용 조성물 및 이의 용도
KR20200028412A (ko) 보존 용액
PE97199A1 (es) Composiciones solubilizadas de sertralina
CU23441A3 (es) Composición agroquímica en suspensión acuosa
RU2010146519A (ru) Композиция биологически активных препаратов для повышения выживаемости осетровых рыб при искусственном воспроизводстве
AR042528A1 (es) Procedimiento para preparar una composicion acuosa blanqueadora de perborato
JP2014198673A (ja) 動物胚の低温保存用の保存剤及び低温での動物胚の保存方法
Achi et al. Effect of Vitamin C Levels in Chicken Egg Yolk Extender on Sperm Motility in Chilled Stored Bull Semen
Minor Gaseous oxygen to improve viability of marginal or pre-damaged organ grafts during hypothermic storage
UA152369U (uk) Спосіб кріоконсервування еритроцитів
AR091707A1 (es) Formulaciones estabilizadas de etanercept

Legal Events

Date Code Title Description
FC Refusal